Original article
Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy
Timoglobulina en dosis bajas vs. basiliximab en receptores de trasplante renal positivos para citomegalovirus: efectividad de una estrategia preventiva modificada
Camilo Monteroa,b,
, Nancy Yomayusaa,b,c, Rodolfo Torresa,b, Jorge Cortesd, Carlos Alvarezb,c, Juan Galloa, Guillermo Aldanaa, Andres Acevedoa,b, Maria Riose, Johana Echeverrie, Zuly Yepese, Adriana Silvaa, Diana Gayona, Jorge Pereza,b,c,e, Milciades Ibaneza,b
Corresponding author
a Renal Transplantation Group, Clinica Reina Sofia, University Clinic, Bogota, Colombia
b Translational Investigation Group, Sanitas University, Clinica Colsanitas, Bogota, Colombia
c Infectious Diseases Department, Clinica Colsanitas, Bogota, Colombia
d Facultad de Medicina, Universidad Nacional de Colombia
e Molecular Biology and Immunology Laboratory, Clinica Colsanitas, Bogota, Colombia
Read
3490
Timeswas read the article
1369
Total PDF
2121
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 23 | 3 | 26 |
| 2025 5 | 105 | 75 | 180 |
| 2025 4 | 89 | 35 | 124 |
| 2025 3 | 124 | 72 | 196 |
| 2025 2 | 107 | 52 | 159 |
| 2025 1 | 86 | 39 | 125 |
| 2024 12 | 53 | 33 | 86 |
| 2024 11 | 69 | 48 | 117 |
| 2024 10 | 64 | 54 | 118 |
| 2024 9 | 76 | 46 | 122 |
| 2024 8 | 97 | 73 | 170 |
| 2024 7 | 62 | 35 | 97 |
| 2024 6 | 79 | 60 | 139 |
| 2024 5 | 82 | 47 | 129 |
| 2024 4 | 67 | 53 | 120 |
| 2024 3 | 52 | 28 | 80 |
| 2024 2 | 58 | 49 | 107 |
| 2024 1 | 35 | 32 | 67 |
| 2023 12 | 49 | 27 | 76 |
| 2023 11 | 61 | 47 | 108 |
| 2023 10 | 73 | 42 | 115 |
| 2023 9 | 72 | 57 | 129 |
| 2023 8 | 154 | 47 | 201 |
| 2023 7 | 87 | 53 | 140 |
| 2023 6 | 57 | 23 | 80 |
| 2023 5 | 46 | 32 | 78 |
| 2023 4 | 32 | 25 | 57 |
| 2023 3 | 37 | 29 | 66 |
| 2023 2 | 32 | 31 | 63 |
| 2023 1 | 45 | 60 | 105 |
| 2022 12 | 34 | 56 | 90 |
| 2022 11 | 14 | 6 | 20 |
Show all
